Trioxifene
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
[2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone | |
Clinical data | |
Legal status | Uncontrolled |
Routes | Oral |
Identifiers | |
CAS number | 63619-84-1 |
ATC code | None |
PubChem | CID 50139 |
ChemSpider | 45471 |
UNII | R0130F043H |
Chemical data | |
Formula | C30H31NO3 |
Mol. mass | 453.57 g/mol |
Trioxifene (LY-133,314) is a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor {alpha} (ER{alpha}) and antagonistic activity against ER{alpha}-mediated gene expression. It has demonstrated anticancer effects in animal studies,[1] indicating that it may be useful for the treatment of breast cancer.
See also
- Selective estrogen receptor modulator
References
- ↑ Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA, Jones CD, Krishnan V, Lynch R, Osborne HE, Graff JR (September 2003). "The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model". Cancer Research 63 (18): 6056–62. PMID 14522935.
|
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.